A peptide MC4R agonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

PG-931

Item No. 41551

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(2→7)-lactam N-acetyl-L-norleucyl-L-α-aspartyl-L-prolyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysyl-L-prolyl-L-valinamide
CAS Number
667430-81-1
Synonyms
  • Ac-Nle-cyclic[Asp-Pro-D-Phe-Arg-Trp-Lys]-Pro-Val-NH2
Molecular Formula
C59H85N15O11
Formula Weight
1180.4
Purity
≥98%
Formulation (Request formulation change)
A neat oil
Peptide Sequence
Ac-Nle-c[DPfRWK]-PV-NH2
Solubility(Learn about Variance in Solubility)
DMSO: Soluble: ≥10 mg/ml
SMILES
O=C(N[C@@H](CCCCNC(C[C@@H](C(N1[C@](CCC1)([H])C(N[C@@H](C(N[C@H](C(N2)=O)CCCNC(N)=N)=O)CC3=CC=CC=C3)=O)=O)NC([C@@H](NC(C)=O)CCCC)=O)=O)C(N4[C@@H](CCC4)C(N[C@H](C(N)=O)C(C)C)=O)=O)[C@@H]2CC5=CNC6=CC=CC=C56
InChi Code
InChI=1S/C59H85N15O11/c1-5-6-20-40(66-35(4)75)51(78)71-45-32-48(76)63-26-13-12-22-42(57(84)73-28-16-25-47(73)56(83)72-49(34(2)3)50(60)77)68-54(81)44(31-37-33-65-39-21-11-10-19-38(37)39)69-52(79)41(23-14-27-64-59(61)62)67-53(80)43(30-36-17-8-7-9-18-36)70-55(82)46-24-15-29-74(46)58(45)85/h7-11,17-19,21,33-34,40-47,49,65H,5-6,12-16,20,22-32H2,1-4H3,(H2,60,77)(H,63,76)(H,66,75)(H,67,80)(H,68,81)(H,69,79)(H,70,82)(H,71,78)(H,72,83)(H4,61,62,64)/t40-,41-,42-,43+,44-,45-,46-,47-,49-/m0/s1
InChi Key
WOFDJLFPEWSAPJ-YEJBJNCVSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $39

    Add

    5 mg

    $174

    Add

    10 mg

    $308

    Add

    25 mg

    $626

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    PG-931 is a peptide agonist of melanocortin receptor 4 (MC4R).1 It increases intracellular cAMP levels in CHO cells expressing MC4R with an EC50 value of 0.42 nM. PG-931 selectively binds to MC4R over MC3R and MC5R (IC50s = 0.58, 55, and 2.4 nM, respectively). It increases mean arterial pressure (MAP), pulse pressure, and respiratory rate in a rat model of hemorrhagic shock in a dose-dependent manner.2 It also prevents multiple organ damage and increases survival in the same model.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Grieco, P., Balse-Srinivasan, P., Han, G., et al. Extensive structure–activity studies of lactam derivatives of MT-II and SHU-9119: Their activity and selectivity at human melanocortin receptors 3, 4, and 5. J. Pept. Res. 62(5), 199-206 (2003).

    2. Giuliani, D., Mioni, C., Bazzani, C., et al. Selective melanocortin MC4 receptor agonists reverse haemorrhagic shock and prevent multiple organ damage. Br. J. Pharmacol. 150(5), 595-603 (2007).